Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Still a Buy?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up before the market opened on Monday . The stock had previously closed at $11.29, but opened at $12.20. Telix Pharmaceuticals shares last traded at $11.80, with a volume of 197,400 shares trading hands.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pixclara (floretyrosine F18), Telix’s amino-acid PET imaging agent for detecting and characterizing gliomas, a form of brain cancer, in adults and children. The approval expands Telix’s commercial product portfolio and could create a new U.S. revenue opportunity, supporting the stock’s rise. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $22 price target, implying substantial upside from the current trading level. The bullish view indicates continued analyst confidence in Telix’s growth prospects following the Pixclara approval. FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $20 price target, adding further support to the positive investor reaction and highlighting expectations for meaningful appreciation. Analyst Ratings for Telix Pharmaceuticals
• Neutral Sentiment: Telix presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event may provide investors with additional information about the company’s pipeline and commercial strategy, although no specific new financial developments were reported in the provided coverage. Telix Pharmaceuticals Presents at Morgan Stanley Healthcare Conference

Analyst Upgrades and Downgrades

Several analysts have recently commented on TLX shares. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Stock Up 8.9%

The company’s 50 day simple moving average is $11.25 and its 200 day simple moving average is $10.24. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Institutional Trading of Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth $120,000. Lazard Asset Management LLC boosted its holdings in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares during the last quarter. Private Advisor Group LLC grew its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the period. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter valued at about $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.